P. Kadiyala

Epigenetic reprogramming of autophagy leads to uncovering a novel therapeutic target for mutant IDH1 astrocytomas

This study identifies autophagy as a critical survival pathway in mIDH1 gliomas and shows that inhibiting autophagy enhances radiosensitivity and tumor regression in preclinical models.

H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Diffuse Hemispheric Gliomas

This study shows that H3.3-G34R mutations reprogram the tumor immune microenvironment in diffuse hemispheric gliomas, enhancing the efficacy of immune stimulatory gene therapy and leading to long-term survival in treated mice.

Analysis of donor pancreata defines the transcriptomic signature and microenvironment of early pre-neoplastic pancreatic lesions

The paper analyzes donor pancreata to define the transcriptomic signature and microenvironment of early pre-neoplastic lesions, finding PanIN lesions are common in healthy individuals and show transcriptional similarity to cancer cells.

Arginase 1 is a key driver of immune suppression in pancreatic cancer

This study shows that Arginase 1 suppresses immune responses in pancreatic cancer by inhibiting T cell activation, and targeting it enhances immunotherapy effectiveness.

Zinc Finger MYND-Type Containing 8 (ZMYND8) is epigenetically regulated in mutant Isocitrate Dehydrogenase 1 (IDH1) glioma to promote radioresistance

This paper identifies ZMYND8 as a gene epigenetically regulated by mIDH1 that promotes radioresistance in glioma cells, and shows its knockdown enhances radiosensitivity.

Systemic delivery of a CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy

This paper develops synthetic protein nanoparticles delivering a CXCR4 inhibitor to treat glioma by enhancing immunotherapy and reducing tumor progression.

The endoplasmic reticulum associated degradation adaptor Sel1L regulates T cell homeostasis and function

This study shows that Sel1L regulates T cell survival, homeostasis, and immune responses by controlling ERAD, mTOR activation, and metabolic processes.

Inhibition of 2-Hydroxyglutrate Elicits Metabolic-reprograming and Mutant IDH1 Glioma Immunity

This study shows that inhibiting 2-hydroxyglutarate in mIDH1 gliomas with ATRX/TP53 inactivation improves survival and induces anti-tumor immunity through immunological memory and reduced T-cell exhaustion.

Systemic Brain Tumor Delivery of Synthetic Protein Nanoparticles for Glioblastoma Therapy

This study develops synthetic protein nanoparticles for GBM therapy, showing they deliver STAT3i siRNA to tumors, enhance radiation response, and induce immune memory in mice.

FYN tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates anti-glioma immune responses

This study shows that FYN tyrosine kinase in glioma cells suppresses anti-glioma immune responses, and its inhibition reduces tumor growth and improves survival in immune-competent models.

Therapeutic efficacy of an immune stimulatory gene therapy strategy in a mouse model of high grade brainstem glioma

This paper tests an immune-stimulatory gene therapy in a mouse model of DIPG, showing increased survival and anti-tumor immunity through adenoviral delivery of TK and Flt3L.